Bayer: Stroke trials
The registry lists 29 Stroke studies with Bayer as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 2 1Phase 3 6No phase 22(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)TerminatedNCT02313909Phase 3Results posted
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseaseCompletedNCT01776424Phase 3Results posted
- Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionCompletedNCT01674647Phase 3Results posted
- Gadobutrol Enhanced MRA of the Supra-aortic VesselsCompletedNCT01344447Phase 3Results posted
- A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular DiseaseCompletedNCT00501059Phase 3Results posted
- A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With WarfarinCompletedNCT05022758
- Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal FunctionCompletedNCT04356989
- Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood VesselsCompletedNCT04097912
- A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)CompletedNCT03887780
- Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial FibrillationCompletedNCT03746301
- Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists EventsCompletedNCT03462446
- Real-world Dosing Patterns of Rivaroxaban in the United StatesCompletedNCT03242278
- Use of Direct Oral Anticoagulants in UKCompletedNCT03119116
- Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional StudyCompletedNCT02784717
- Real-world Comparative Effectiveness of Rivaroxaban Versus VKACompletedNCT02690155
- Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K AntagonistCompletedNCT02687867
- Real-world Comparative Effectiveness of Apixaban Versus Vitamin K AntagonistCompletedNCT02687854
- An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care CentersCompletedNCT02559232
- Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)CompletedNCT02550717
- Real-Life Evidence on Stroke Prevention in SPAFCompletedNCT02485873
- An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care CentresCompletedNCT02470767
- Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of SpainCompletedNCT02262676
- Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation PatientsCompletedNCT01925755
- Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic EmbolismCompletedNCT01855139
- Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01839357Phase 3
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA RegionCompletedNCT01800006
- Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in AsiaCompletedNCT01750788
- Xarelto for Prevention of Stroke in Patients With Atrial FibrillationCompletedNCT01606995
- Repinotan in Patients With Acute Ischemic StrokeCompletedNCT00044915Phase 2